- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Patent holdings for IPC class A61P 1/16
Total number of patents in this class: 7755
10-year publication summary
|
239
|
290
|
514
|
603
|
721
|
840
|
925
|
826
|
655
|
362
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10867 |
61 |
| Genfit | 269 |
58 |
| Gilead Sciences, Inc. | 2032 |
57 |
| Daiichi Sankyo Company, Limited | 1865 |
53 |
| Albireo AB | 169 |
49 |
| Sunshine Lake Pharma Co., Ltd. | 597 |
48 |
| Eli Lilly and Company | 3834 |
45 |
| Osaka University | 3374 |
45 |
| The Regents of the University of California | 19868 |
41 |
| Takeda Pharmaceutical Company Limited | 2711 |
40 |
| Bristol-myers Squibb Company | 4878 |
38 |
| Pfizer Inc. | 3379 |
33 |
| Chugai Seiyaku Kabushiki Kaisha | 1349 |
33 |
| InterCept Pharmaceuticals, Inc. | 209 |
31 |
| Viking Therapeutics, Inc. | 51 |
31 |
| AstraZeneca AB | 2917 |
29 |
| Boehringer Ingelheim International GmbH | 4695 |
29 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3367 |
29 |
| Kowa Company, Ltd. | 1197 |
29 |
| Regeneron Pharmaceuticals, Inc. | 4246 |
28 |
| Other owners | 6948 |